#6193 multicenter retrospective study evaluating the clinical picture and outcome of the sars-cov2 infection among patients with glomerular diseases

Abstract Background and Aims This is a retrospective study aiming to describe the clinical picture and outcome of sars-cov2 infection in patients with glomerular diseases (GD) and its impact in the probability of relapse of the primary disease. Methods Patients with biopsy-broven GD, who had been infected by sars-cov2 were studied. Patients who ended up in end-stage kidney disease prior to infection were excluded. We recorded demographics, histopathological diagnosis, past medical history, immunosuppressive regimens which were given for the GD, status of GD at the time of infection, clinical picture and outcome of the infection including specific symptoms, requirement for hospitalization, duration of hospitalization and outcome of Covid-19. The probability of relapse following Covid-19 was also estimated in patients who were infected and those who did not. Results To date 312 patients have been included in the study, of whom 214 (68,5%) were diagnosed with Covid-19, while the remaining 98 did not. Infected patients were younger compared with those not infected [44 (28-59.75) vs. 53 (38-64) years, p<0.001]. The mean time from the diagnostic biopsy to Covid-19 was 67,6(±59,3) months. 82,5% of the infected patients were vaccinated against sars-cov2 and 49,1% were treated with immunosuppressive therapy at vaccination. 28(13%) of the infected patients required admission to hospital, with a mean duration of 8,3(±5,1) days. 84,2% of the infected patients experienced complete recovery of the infection, 4 (1,9%) died due to Covid-19 and 24 (11%) had Covid-19 related symptoms for more than 3 months. Among patients who had achieved remission of the GD prior to the infection, the frequency of relapse of the primary disease was higher in patients with Covid-19 versus not infected patients (11.9% vs. 2.1%, p = 0.007). Conclusions According to our findings, the sars-cov2 infection appears to have a significant impact in patients with GD not only due to the increased morbidity but also by increasing the probability for relapse of the primary disease.